Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research ana ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of ...

The U.S. hedge fund, which manages around $70 billion in assets, is one of Wall Street's most influential investors, known for pressuring companies to fire management, break apart and spin off ...

Real-time index price for TSX Global Mining Index (TXGM), along with buy or sell indicators, analysis, charts, historical ...

As the quarterly earnings season continues, the upcoming week promises a flurry of reports from some of the most influential companies spanning various industries. In the consumer sector, Coca-Cola ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...

The focus of Wall Street investors in the week ahead will be primarily on expected reciprocal trade tariffs by US President ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers ...

Such programmes still qualify for a limited waiver, which will expire towards the end of April, but only for approved ...

South African projects funded through the President’s Emergency Plan for Aids Relief, Pepfar, are exempted — at least until the end of April — from the executive order that US President Donald Trump ...